Stay updated with breaking news from Mapi Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The long-acting glatiramer acetate therapy GA Depot was found to ease disability in patients with relapsing forms of MS in a Phase 3 trial.
New recommendations help clinicians communicate technical information to help patients with multiple sclerosis achieve better understanding and self-care.
Reaffirms 2022 Guidance Ranges [1] Across Total Revenues, Adjusted EBITDA and Free Cash Flow; Driven by Solid Operating Momentum Despite Foreign Exchange...
GA Depot is a Potential Long Acting Injection Solution for Multiple Sclerosis Patients Positive Results from Phase III GA Depot Study in Relapsing MS to...
The results found similar efficacy to existing treatments but with reduced side-effects such as less daytime drowsiness.